Back to Search
PAMELA SCHAFER, M.D.
M.D.
Specialist
NPI: 1548385123Individual
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
G85240(CA)4624(ND)32327(MN)
Research & Publications (20)
Hypoxia-inducible factor-1alpha signaling in aquaporin upregulation after traumatic brain injury.
PMID 19429018·Neurosci Lett·2009
7-preclinical
Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.
PMID 19256507·J Med Chem·2009
7-preclinical
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
PMID 19009291·Cancer Immunol Immunother·2009
7-preclinical
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
PMID 18805433·Microvasc Res·2009
7-preclinical
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
PMID 18628480·Clin Cancer Res·2008
8-other
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.
PMID 18172279·Clin Cancer Res·2008
7-preclinical
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
PMID 17640369·J Transl Med·2007
7-preclinical
Neighborhood mapping and evaluation: a methodology for participatory community health initiatives.
PMID 17295067·Matern Child Health J·2007
8-other
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
PMID 17234786·Cancer Res·2007
8-other
Reactivation and growth of non-culturable indicator bacteria in anaerobically digested biosolids after centrifuge dewatering.
PMID 17107701·Water Res·2007
7-preclinical
Ethnographically informed community evaluation: a framework and approach for evaluating community-based initiatives.
PMID 17103327·Matern Child Health J·2007
8-other
Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.
PMID 16510725·J Neurosci·2006
4-observational
Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly.
PMID 16494942·Leuk Res·2006
8-other
The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity.
PMID 16424030·Cancer Res·2006
7-preclinical
Keynote review: phosphodiesterase-4 as a therapeutic target.
PMID 16257373·Drug Discov Today·2005
6-review
Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT.
PMID 16241859·J Interferon Cytokine Res·2005
8-other
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.
PMID 15797261·Microvasc Res·2005
7-preclinical
Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner.
PMID 15598423·Cell Immunol·2004
8-other
Potential new therapeutics for Waldenstrom's macroglobulinemia.
PMID 12720152·Semin Oncol·2003
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1343 STRATFORD CT
DEL MAR, CA 92014 - Phone
- (858) 523-9409
Quick Facts
- NPI
- 1548385123
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile